38 results about "Bordetella sp" patented technology

The invention relates to technical field of microbial inoculant culture, and especially relates to a medium of a composite bacterium for culture treatment coking wastewater, and its application. The medium for enlarged culturing of the composite bacterium for culture treatment coking wastewater is a medium II; and pseudomonades, Acinetobacter, Bordetella sp., Klebsiella pneumoniae, Bacillus megaterium and Bacillus subtilis are cultured in the medium II to prepare a treatment coking wastewater inoculant in order to remove pollutants in the coking wastewater. The quantity of bacteria obtained by culturing the above mixed bacteria in the medium II is 1.5-2.5 times the quantity of bacteria obtained by using a conventional LB medium, and the cost of the medium II only accounts for 50-70% of the cost of the conventional LB medium.

Diagnostic testing and immunomonitoring that uses genetically detoxified Bordetella pertussis CyaA as a delivery system are effective in tracking any immune responses, such as those generated by infectious and non-infectious diseases, or vaccinations, for example. T cells previously stimulated by a given antigen can be restimulated in vitro by the same antigen fused or chemically coupled to CyaA or a fragment thereof. The invention includes diagnostic tests and immunomonitoring for tuberculosis by providing a delivery system, which can deliver the M. tuberculosis immunodominant proteins ESAT-6 and CFP-10, to human cells and non-human animal cells, such as cattle. In addition, fusion proteins between CyaA and cancer antigens are also provided as diagnostic tests and immunomonitoring systems for cancers, such as melanoma.

This invention relates to an immunogenic composition comprising a bacterial extract containing at least one expression products of the vrg genes of a strain of Bordetella chosen from B. pertussis, B. parapertussis, or B. bronchiseptica. The invention also relates to a method for producing the extract, comprising culturing the bacteria on blood medium to obtain isolated nonhemolytic colonies; inoculating cells of one or more colonies in liquid medium to give a suspension of cells; separating the cells from the liquid medium after culture; suspending the separated cells in a buffer comprising urea for at least an amount of time sufficient to form a bacterial lysate; and separating intact cells and insoluble material from soluble material, wherein the extract comprises the soluble material.

An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.

This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona.

The invention discloses a fungicide for removing and / or degrading polycyclic aromatic hydrocarbon and application thereof. The invention provides a fungicide of which the active ingredients are (Rhodococcus sp.) LU3 CGMCC No.3610, (Microbacterium sp.) LU1 CGMCC No.3581, (Ochrobacterium sp.) LU2CGMCC NO.3582 and (Bordetella sp.) LU4 CGMCC No.3611. The experiment of the invention shows: after fourweeks, the strainaway rate of 16 types of polycyclic aromatic hydrocarbon in soil added with the fungicide is averagely improved by 30% if being compared with that of soil which is not added with thefungicide, wherein the strainaway rate of six types of low-cyclic (two / three cyclic) polycyclic aromatic hydrocarbon is averagely improved by 26%, and the stainaway rate of ten types of middle and high cyclic (more than four cycle) polycyclic aromatic hydrocarbon is averagely improved by 32%.

The present invention relates to bacterial strains, in particular for use in the field of vaccines, in particular in the prevention or treatment of infections caused by Bordetella bacteria.

A method of reducing or preventing the development of airway inflammation in a subject comprising the step of infecting the subject's respiratory tract with an amount of a composition comprising a pharmaceutically acceptable carrier and sufficient to colonize the subject Respiratory attenuated B. pertussis adhesin-deficient live bacteria of the genus Bordetella. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacterium results in reducing or preventing the development of airway inflammation in the subject.

The invention relates to a 6-aminopenicillanic acid (6-APA) degrading bacterium and a screening method thereof. Particularly, the invention relates to a strain of 6-APA degrading bacterium Bordetella sp.L2, which is preserved in China General Microbiological Culture Collection Center (CGMCC) on October 18, 2012, with the preservation number of CGMCC No. 6691; and the GenBank registration number of the 16S rRNA gene sequence of the 6-APA degrading bacterium Bordetella sp.L2 is HQ840720. The 6-APA degrading bacterium Bordetella sp.L2 is an aerobic bacillus brevis; and when the pH value is 8.0, the 6-APA degradation rate of the 6-APA degrading bacterium Bordetella sp.L2 is 28%. The strain achieves higher 6-APA degradation capability and has a practical significance and an important engineering application value for treatment of waste water containing 6-APA cephalosporin.

The invention relates to a chimeric protein comprising or consisting of, from N-terminal to C-terminal, (a) a N-terminal part of a Bordetella CyaA protein (b) a heterologous polypeptide comprising antigens originating from different HPVs, and (c) a C-terminal part of a Bordetella CyaA protein. The invention also relates to a polynucleotide encoding this chimeric protein. A composition comprising at least one chimeric protein(s) of the invention and the prophylactic and / or therapeutic uses of said composition are also part of the invention.

The invention discloses a Bordetella strain and its application in preparing cholesterol oxidase and cholest-4-en-3-one. The strain is Bordetella sp. B4 CGMCC No.2229, which can synthesize extracellular cholesterol oxidase and convert cholesterol into cholest-4-en-3-one. The strain of the invention has the characteristics of short fermentation time and high enzyme production activity, and the extracellular enzyme activity can reach 2000U / L, which has reached or exceeded the international leading level.

Stable, immunogenic combination vaccine(s) comprising a mixture of antigens for prevention and prophylaxis of infections caused by Rotavirus, Poliomyelitis virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and Hepatitis B virus. A multivalent combination vaccine comprises i) significantly dose-reduced Salk-IPV or Sabin-IPV (IPV) antigens prepared by methods of formaldehyde inactivation and alum hydroxide adsorption resulting in maximum D-antigen recovery; ii) Injectable heat inactivated Rotavirus antigen(s) providing broad cross-protective immunity among human rotavirus strains; iii) Hib PRP-carrier protein conjugate having improved stability and immunogenicity; iv) whole cell pertussis antigen with improved immunogenicity and stability; and v) Homogenous fractions of Diphtheria and Tetanus toxoids. Such stable and immunogenic vaccine compositions are made by i) individually adsorbing dose reduced IPV, IRV antigens on alum hydroxide and keeping other antigen(s) unadsorbed or adsorbed on alum phosphate, alum hydroxide, or a combination thereof; and ii) using an order of addition of antigens during blending.